642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Combination Small Molecules


Alessandra Tedeschi, Emmanuelle Ferrant, Ian W. Flinn, et al.

Zanubrutinib plus venetoclax is generally well-tolerated in this high-risk population. There were no new safety signals and no TLS was reported. Updated data on safety, efficacy, and biomarkers will be presented in the oral session.



Paolo Ghia, John N. Allan, Tanya Siddiqi, et al.

The results of first-line ibrutinib plus venetoclax in CLL patients with confirmed uMRD, according to the study authors, support the potential for treatment-free remission with fixed-duration treatment, even in patients with high-risk characteristics. High uMRD rates (2-year DFS rate 95% and 3-year PFS rate ≥95) were achieved. The safety profile of ibrutinib + venetoclax was congruent with the known safety profile for both active substances.



Carsten Utoft Niemann, Julie Dubois, Christian Brieghel, et al.

MRD-controlled time-limited treatment with ibrutinib and venetoclax for R/R-CLL could be carried out without progression after end-of-treatment. It results in a favorable risk-benefit profile without any new safety signals. In patients who were again MRD-positive the therapy could be successfully restarted. From this the study authors conclude that MRD-guided termination and resumption of targeted therapy in CLL is possible.



Tahla Munir, Carol Moreno, Carolyn Owen, et al.

Fixed-duration ibrutinib plus venetoclax orally demonstrated superior uMRD responses in elderly or unfit patients with previously untreated CLL. This was deeper and more sustainable than with chlorambucil plus obinutuzumab. See abstract for more info. 



Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, et al.

The time-limited therapies of GVe and GIVe showed superior uMRD rates in PB compared to CIT at 15 months. The uMRD rates in BM and CRR, especially for GVe and GIVe, were higher than in CIT. The safety profile was good in all arms.